• Product nameAnti-CCM2 antibody
    See all CCM2 primary antibodies
  • Description
    Goat polyclonal to CCM2
  • SpecificityThis antibody is expected to recognize both reported isoforms (NP_001025006.1 and NP_113631.1).
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow, Dog
  • Immunogen

    Synthetic peptide:


    , corresponding to internal sequence amino acids 23-35 of Human CCM2

  • Positive control
    • Human heart lysate.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 0.5% BSA, Tris saline, pH 7.3
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab53557 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesPeptide ELISA: antibody detection limit dilution 1:128,000.

    WB: Use at a concentration of 0.03 - 0.1 µg/ml. Detects a band of approximately 49 kDa (predicted molecular weight: 49 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionMay function as a scaffold protein for MAP2K3-MAP3K3 signaling. Seems to play a major role in the modulation of MAP3K3-dependent p38 activation induced by hyperosmotic shock.
    • Involvement in diseaseDefects in CCM2 are the cause of cerebral cavernous malformations type 2 (CCM2) [MIM:603284]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and are usually present clinically during the 3rd to 5th decades of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.
    • Sequence similaritiesContains 1 PID domain.
    • Cellular localizationCytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • C7orf22 antibody
      • Ccm2 antibody
      • CCM2 gene antibody
      • CCM2_HUMAN antibody
      • Cerebral cavernous malformation 2 antibody
      • Cerebral cavernous malformations 2 protein antibody
      • Chromosome 7 open reading frame 22 antibody
      • Malcavernin antibody
      • MGC4067 antibody
      • MGC4607 antibody
      • MGC74868 antibody
      • OSM antibody
      • Osmosensing scaffold for MEKK3 antibody
      • OTTHUMP00000159554 antibody
      • OTTHUMP00000214270 antibody
      • OTTHUMP00000214271 antibody
      • OTTHUMP00000214273 antibody
      • PP10187 antibody
      see all

    Anti-CCM2 antibody images

    • Anti-CCM2 antibody (ab53557) at 0.03 µg/ml + Human Heart lysate (35µg protein in RIPA buffer)

      Predicted band size : 49 kDa
      Observed band size : 49 kDa

    References for Anti-CCM2 antibody (ab53557)

    ab53557 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab53557.
    Please use the links above to contact us or submit feedback about this product.